Data investigation

503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1

A 503A pharmacy compounds per patient under a state board. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected and must report adverse events. What each means for compounded GLP-1s, and how to check yours.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
10 min read·12 citations

A 503A pharmacy is a state-licensed pharmacy that compounds a drug for one named patient against a prescription. Its state board of pharmacy oversees it day to day, it does not have to follow federal manufacturing rules (CGMP), and federal law does not make it report side effects to FDA.[1][4][10] A 503B outsourcing facility chooses to register with FDA. In return it must meet CGMP, is inspected by FDA on a risk-based schedule, must report adverse events, and may supply clinics without a patient name on the order.[1][2] FDA’s register listed 100 outsourcing facilities as of November 2026.[3] Of the 70 pharmacies we track behind telehealth GLP-1 sellers, 62 do not appear on that register. A pharmacy that is not on it is usually a state-licensed 503A pharmacy, which its state license confirms.

About this article. The rules here are quoted from FDA’s own compounding pages and from the Federal Food, Drug, and Cosmetic Act itself. Register figures are calculated from FDA’s published list of outsourcing facilities (November 2026 copy) and from the GLP Watchdog pharmacy register. Neither type of pharmacy makes an FDA-approved drug, and neither label is a guarantee about a particular vial.

503A vs 503B: the differences side by side

Section 503A and section 503B of the FD&C Act, compared
503A compounding pharmacy503B outsourcing facility
Who it isA licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physicianA facility at one address that compounds sterile drugs and has chosen to register with FDA
Main regulatorState board of pharmacy (FDA can inspect for surveillance or cause)FDA
Registers with FDA as an outsourcing facilityNoYes, and pays FDA fees
Federal manufacturing rules (CGMP)ExemptRequired
FDA inspectionsSurveillance and for-cause inspections onlyRisk-based schedule set by FDA
PrescriptionNeeded for an identified patient; limited advance batches allowedCan fill a patient prescription or a clinic order with no patient named
Adverse event reports to FDANot required by federal lawRequired
Reports what it makes to FDANot requiredYes: on registering, then every June and December
Bulk ingredient may come fromA USP/NF monograph, a component of an approved drug, or the 503A bulks listThe 503B bulks list, or a drug on FDA's shortage list at the time
Copies of approved drugsNot regularly or in inordinate amountsNot essentially a copy of an approved drug

Each row comes from the statute or from FDA’s description of it.[1][2][4][6][7][8][9] The sections below take the rows that matter most if you are buying compounded semaglutide or tirzepatide.

What a 503A pharmacy is

Section 503A is the older route. It is what most people picture when they hear “compounding pharmacy”: a pharmacist preparing a medicine for one patient. The law gives the drug an exemption from FDA approval, CGMP and some labeling rules, but only if it is compounded for a particular person.[1]

…compounded for an identified individual patient based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient…
— 21 U.S.C. 353a(a), section 503A of the FD&C Act

A 503A pharmacy may make a batch ahead of time, but only “in limited quantities” and only based on a history of prescriptions it has received.[8] It cannot fill a clinic’s order for office stock with no patient named; that is the 503B route.[1] The statute also caps out-of-state shipping at 5% of the pharmacy’s prescriptions unless its state has signed a memorandum of understanding with FDA.[8]

Oversight happens mostly at the state level. In FDA’s words, “state boards of pharmacy have primary responsibility for the day-to-day oversight” of these pharmacies, while FDA “does conduct surveillance and for-cause inspections” of them.[4] A 503A pharmacy is not held to CGMP, the standard drug makers follow.[4] Federal law also does not require it to report adverse events to FDA. FDA says this means side effects from compounded GLP-1s are probably underreported.[10]

Where a 503A pharmacy gets its ingredient

A 503A pharmacy may only compound from a bulk ingredient that meets one of three tests: it follows a USP or NF monograph, it is a component of an FDA-approved drug, or it is on FDA’s 503A bulks list.[6] Semaglutide and tirzepatide are components of approved drugs, so a 503A pharmacy can use them as ingredients. What limits it is a different rule.

The “essentially a copy” limit

Section 503A bars a pharmacy from compounding, “regularly or in inordinate amounts,” drugs that are “essentially copies of a commercially available drug product.”[8] A change made for one patient that the prescriber decides makes “a significant difference” for that patient does not count as a copy.[8] FDA has said it does not intend to act against a pharmacy that fills four or fewer prescriptions of a copy in a calendar month.[5] FDA has also said that adding vitamin B12 to semaglutide may still count as a copy.[5] A telehealth program shipping the same formula to thousands of members is far past four a month. That is why the “personalized dose” language on seller sites matters to their legal position.

Sellers usually say which kind they use in an FAQ or the terms. Embody, for example, describes its four named partner pharmacies as state-licensed 503A compounding pharmacies.

Astra lists six pharmacies that compound for its patients, each marked as a 503A compounding pharmacy, from Hallandale Pharmacy in Fort Lauderdale to Drug Crafters in Frisco, Texas. The Sanctuary Wellness Institute says all its compounded semaglutide and tirzepatide are prepared at MFV Pharmacy, a licensed compounding pharmacy in Utah. Forever Health Rx says a state-licensed 503A compounding pharmacy prepares its medication, and names The Pharmacy Hub.

What a 503B outsourcing facility is

Section 503B was added by the Drug Quality and Security Act, enacted on November 27, 2013.[1] Congress passed it after the 2012 meningitis outbreak, which FDA links to contaminated drugs from a Massachusetts compounding pharmacy: more than 750 infections and more than 60 deaths.[1] The law created a new, voluntary category of compounder.

The law defines an outsourcing facility as a facility at one geographic location or address that is engaged in the compounding of sterile drugs; has elected to register as an outsourcing facility; and complies with all of the requirements of section 503B.
— FDA, Information for Outsourcing Facilities

The trade-off is scale for scrutiny. An outsourcing facility can compound without a patient-specific prescription. It can fill a hospital or clinic order for office stock.[1] In return:

  • CGMP applies. 503B drugs are exempt from FDA approval but not from current good manufacturing practice.[2]
  • FDA inspects. The statute directs FDA to inspect outsourcing facilities on a risk-based schedule. That schedule weighs compliance history, recalls and other factors.[9]
  • Adverse events must be reported. “Outsourcing facilities shall submit adverse event reports” to FDA.[9]
  • FDA gets a product list. Each facility tells FDA what it compounded in the last six months when it registers, then every June and December.[2][9]
  • The label names the maker. A 503B label must carry “This is a compounded drug.” and the facility’s name, address and phone number. It must also show a lot number, the compounding date, an expiration date and “Not for resale.” If the drug was not dispensed on a prescription for a named patient, it must also say “Office Use Only.”[9]
  • No middlemen. Only the facility that made the drug may sell or transfer it. Giving it in a health care setting or dispensing it on a prescription is still allowed.[9]

An outsourcing facility is also barred from compounding anything the statute calls “essentially a copy of one or more approved drugs.”[9] It may only start from a bulk ingredient on the 503B bulks list, or for a drug on FDA’s shortage list “at the time of compounding, distribution and dispensing.”[7] Being a component of an approved drug does not help here, unlike under 503A. That is a narrower door for GLP-1s.

Which is safer, 503A or 503B?

Neither is FDA-approved. FDA does not review either kind of compounded drug for safety, effectiveness or quality before it reaches patients.[1] The difference is who checks the building and how often. A 503B facility answers to FDA and to manufacturing-grade standards. A 503A pharmacy answers mainly to its state board.[4] Some sellers say which kind fills their orders. Brello Health says it ships from a US-based 503A pharmacy and names that pharmacy in its terms, while Amble says its medication may come from either kind without saying which one fills a given order.

Registration is also not the same as inspection. Of the 100 facilities on FDA’s register in the November 2026 copy, 43 were marked “Not yet inspected” and 57 had an inspection date.[3] Most of the uninspected ones registered recently. The breakdown is in our analysis of FDA’s outsourcing facility register. A 503B name on a box tells you which rules apply. It does not tell you the last inspection went well.

Two things hold for both. FDA can act against either on quality grounds, whatever the shortage status.[5] And because 503A pharmacies do not have to report side effects to FDA, nobody has a full count of harms from compounded GLP-1s. What FDA’s adverse event reports can and cannot show covers that gap.

What changed for compounded GLP-1s when the shortages ended

While semaglutide and tirzepatide were on FDA’s shortage list, both routes had room. The 503A copy limit applies to drugs that are “commercially available,” and FDA generally treats a drug as commercially available once its shortage is resolved. 503B facilities could compound from bulk only because the drugs were on the shortage list.[5][7] When the shortages ended, FDA gave each route a separate grace period. 503A pharmacies got 60 calendar days and 503B facilities got 90.[5]

When FDA's grace period for shortage-based GLP-1 compounding ended
DrugShortage declared resolved503A grace period ended503B grace period ended
Tirzepatide (Mounjaro, Zepbound)December 19, 2024February 18, 2025 (in effect after a court denied an injunction on March 5, 2025)March 19, 2025
Semaglutide (Ozempic, Wegovy)February 21, 2025April 22, 2025 (court denied an injunction on April 24, 2025)May 22, 2025

FDA’s own timeline is the source for every date in the table.[5] The grace periods only covered violations tied to the shortage. FDA said it could still act on anything else, including “findings that a product may be of substandard quality or otherwise unsafe.”[5]

The routes now look different. Semaglutide or tirzepatide can still come from a 503A pharmacy when the patient’s prescriber documents a significant clinical difference, or when the pharmacy stays within the four-a-month limit on copies.[5][8] A 503B facility has a harder problem. Neither drug is on the shortage list or the 503B bulks list.[5] On April 30, 2026, FDA proposed keeping semaglutide, tirzepatide and liraglutide off that list for good. In FDA’s assessment, outsourcing facilities have no clinical need to make them from bulk ingredients.[11]

When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.
— FDA Commissioner Marty Makary, April 30, 2026

FDA later extended the comment period to July 30, 2026.[12] As of October 2026, no final decision has appeared in the Federal Register. Which GLP-1s can be compounded follows that decision and the shortage history in more detail.

How to find out which kind of pharmacy filled your GLP-1

FDA notes that people who buy compounded drugs online “may not know the identity of the compounder that produced the drug.”[4] You can usually find out in a few steps.

  1. Read the vial and the pharmacy label. A 503B product must name the outsourcing facility, with its address and phone number, and say “This is a compounded drug.”[9] A 503A label follows state rules; look for the name of the dispensing pharmacy. If the seller will not name the pharmacy, nothing else here can be checked.
  2. Search the name on FDA’s outsourcing facility register. If it is there, the pharmacy is a 503B facility, and the register shows its last FDA inspection.[3] Our pharmacy legitimacy lookup checks that register along with FDA warning letters and recalls in one search. Of the 70 pharmacies in the GLP Watchdog pharmacy register, 8 match FDA’s 503B register by name, city and state.
  3. If it is not there, check the state license. Not being on the federal register is normal for a 503A pharmacy. 62 of the 70 pharmacies we track are not on it. The next step is the license lookup on the board of pharmacy website for the state where the pharmacy is located.[4]
  4. Notice “Office Use Only.” Federal law requires this phrase on 503B drugs that were not dispensed on a prescription for a named patient.[9] A vial with that phrase that arrived at your home in your name should prompt a question to the seller.
  5. Make sure the pharmacy actually exists and made the drug. FDA has found compounded semaglutide and tirzepatide with labels naming pharmacies that do not exist. It has also found labels naming real pharmacies that did not make the product.[10] Call the pharmacy on the label using a number you find yourself, not the one on the vial.
  6. Check enforcement history. FDA warning letters to GLP-1 sellers and pharmacies lists the letters that name compounded semaglutide or tirzepatide.

The pharmacies in our register that match FDA’s 503B register are Empower Pharmacy, Olympia Pharmaceuticals, Wells Pharma of Houston, ProRx, Tailstorm Health, FarmaKeio Outsourcing, BPI Labs and MedisourceRx.

Step one is easier when the seller names the pharmacy before you buy. Strive Pharmacy is itself a 503A compounding pharmacy in Arizona and Texas; it fills prescriptions from outside clinicians and does not sell to consumers directly. Zera Health and Revive Longevity both name Strive as the pharmacy that fills their orders. Risen Labs names Olympia Pharmacy and describes it as a 503A compounder.

Other sellers list more than one pharmacy, so the name on your label depends on which one filled the order. NuviaRx names Manifest Pharmacy and RX Compounding Store, and Revel RX names Manifest Pharmacy and Red Rock Home Pharmacy. Southern Vitality and Weight Loss lists PerfectRX, The Pharmacy Hub and Rx Compounding Store, while TeleWellnessMD lists 1st Choice Pharmacy and National Health Rx. Big Easy Weight Loss lets you choose the pharmacy, with Hallandale, OptioRx and Miller’s among those it lists, and NuDay Rx names Belmar Pharmacy. Each name still goes through steps two and three above.

Idun Rx names the same pair as NuviaRx, Manifest Pharmacy and RX Compounding Store. So does TomorrowsRX, which says either may fill a prescription depending on the therapy and medication. RenewMD gives a street address for each of its four, among them Triad Rx in Daphne, Alabama, and Health Warehouse in Florence, Kentucky.

The same two-route system applies beyond GLP-1s. Peptides that are not components of an approved drug face the bulks-list rules described in are peptides legal. Six of those peptides got a narrower opening on October 28, 2026, through an HHS policy that covers 503A compounding only, not 503B outsourcing facilities, and only under its conditions; see the HHS peptide policy. What clinics sell as peptide therapy, and which of it is an approved drug, is covered separately. The prescription rules for each route are covered in whether compounded semaglutide needs a prescription.

Frequently Asked Questions

A 503A pharmacy is licensed by its state, compounds for one individual patient against a prescription, and answers mainly to its state board of pharmacy. A 503B outsourcing facility registers with FDA, must follow current good manufacturing practice, is inspected by FDA on a risk-based schedule, must report adverse events, and may fill clinic orders that name no patient.
No. Registration is not approval. Drugs made by an outsourcing facility are exempt from FDA approval, so FDA has not reviewed them for safety, effectiveness or quality. Registration means the facility is subject to manufacturing rules, FDA inspection and adverse event reporting, and some registered facilities have not yet been inspected.
No. FDA says federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events, which is why it believes side effects from compounded GLP-1s are likely underreported. Outsourcing facilities are required to report them.
Not from bulk ingredient under the shortage route. FDA's grace period ended on March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide. Neither drug is on the 503B bulks list, and on April 30, 2026 FDA proposed keeping both, along with liraglutide, off it. The comment period closed July 30, 2026.
Find the pharmacy name on your label, then search it on FDA's list of registered outsourcing facilities. If it is listed, it is a 503B facility. If it is not, it is most likely a 503A pharmacy, and you can confirm its license with the pharmacy board of the state it operates from.

References

  1. 1.U.S. Food and Drug Administration Human Drug Compounding Laws FDA. 2024. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
  2. 2.U.S. Food and Drug Administration Information for Outsourcing Facilities FDA. 2022. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
  3. 3.U.S. Food and Drug Administration Registered Outsourcing Facilities FDA. 2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  4. 4.U.S. Food and Drug Administration Compounding and the FDA: Questions and Answers FDA. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. 5.U.S. Food and Drug Administration FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  6. 6.U.S. Food and Drug Administration Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act FDA. 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  7. 7.U.S. Food and Drug Administration Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act FDA. 2025. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  8. 8.U.S. Congress 21 U.S. Code § 353a: Pharmacy compounding (FD&C Act section 503A) Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/21/353a
  9. 9.U.S. Congress 21 U.S. Code § 353b: Outsourcing facilities (FD&C Act section 503B) Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/21/353b
  10. 10.U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  11. 11.U.S. Food and Drug Administration FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  12. 12.Food and Drug Administration List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period Federal Register. 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

How Long Do Semaglutide and Tirzepatide Side Effects Last?

What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.

11 min read

Buying Tirzepatide as a Research Chemical: What "Research Use Only" Really Means

"Research use only" is the seller's legal position on what they are handing you, not a grade. It removes the licensed dispenser, the accountable prescriber and every route to recourse.

7 min read

GLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says

A boxed warning about thyroid C-cell tumors sits on every semaglutide and tirzepatide label there is. It comes from rodent studies, the labels themselves say the human relevance is undetermined, and the human research published since does not agree with itself.

11 min read

How Much Does Compounded Semaglutide Cost? What Drives the Number

Compounded GLP-1 prices are quoted in ways that hide what you will be charged. This is the structure of the bill, and where on this site the dated numbers live.

9 min read

GLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing

Two distinct eye questions get merged into one headline. Diabetic retinopathy complications are on the semaglutide label and trace to blood sugar falling fast; NAION is a separate optic-nerve signal that Europe's drug-safety committee recommended adding to product information in June 2025, and US labeling still does not mention.

12 min read

Tirzepatide Long-Term Side Effects: Where the Evidence Stops

The longest published randomized tirzepatide treatment in obesity is 176 weeks, and the cardiovascular trial ran a median of 46.9 months. This separates what the approved label warns about from what a trial counted, and says where the record ends.

11 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

bmiMD

Starting below a standard dose, with microdose tiers

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →